Hudson Bay Capital Management LP Makes New Investment in Abivax SA Sponsored ADR $ABVX

Hudson Bay Capital Management LP purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 91,062 shares of the company’s stock, valued at approximately $7,731,000. Hudson Bay Capital Management LP owned 0.12% of Abivax as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of ABVX. EverSource Wealth Advisors LLC grew its stake in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares during the last quarter. First Horizon Corp bought a new position in Abivax during the 3rd quarter worth $36,000. Bank of America Corp DE raised its position in Abivax by 56.1% during the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after purchasing an additional 1,990 shares during the last quarter. Hantz Financial Services Inc. acquired a new position in Abivax during the 3rd quarter worth about $52,000. Finally, Cubist Systematic Strategies LLC lifted its holdings in Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after buying an additional 2,595 shares during the period. Institutional investors own 47.91% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on ABVX. Jefferies Financial Group initiated coverage on Abivax in a research note on Monday, March 16th. They issued a “buy” rating and a $160.00 price target for the company. Citigroup reaffirmed a “market outperform” rating on shares of Abivax in a research note on Thursday, January 8th. Citizens Jmp increased their target price on shares of Abivax from $114.00 to $131.00 and gave the company a “market outperform” rating in a research report on Tuesday, December 16th. Guggenheim restated a “buy” rating and set a $175.00 price target on shares of Abivax in a report on Thursday, December 18th. Finally, Oppenheimer set a $131.00 price target on shares of Abivax in a research report on Thursday, January 8th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $136.69.

Abivax Stock Down 2.2%

Abivax stock opened at $120.34 on Friday. Abivax SA Sponsored ADR has a fifty-two week low of $4.77 and a fifty-two week high of $148.83. The company has a debt-to-equity ratio of 0.03, a quick ratio of 7.86 and a current ratio of 7.86. The firm’s 50-day simple moving average is $119.35 and its 200 day simple moving average is $110.17. The stock has a market cap of $9.52 billion, a PE ratio of -28.79 and a beta of 1.00.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.